- Prestige Consumer Healthcare Inc. Reports Fiscal Year 2024 Results
- Prestige Consumer Healthcare Inc. to Release Fiscal 2024 Fourth Quarter and Year-End Earnings Results
- Dramamine® Celebrates its 75th Anniversary by Reviving an Unexpected Partner: The Barf Bag
- Prestige Consumer Healthcare Inc. Reports Third Quarter Fiscal 2024 Results
- Insight Pharmaceuticals Issues Voluntary Nationwide Recall of TING® 1% Tolnaftate Athlete’s Foot Spray Antifungal Spray Liquid Due to the Presence of Benzene
- Prestige Consumer Healthcare Inc. to Release Fiscal 2024 Third Quarter Earnings Results
- Insight Pharmaceuticals Issues Voluntary Nationwide Recall of Americaine® 20% Benzocaine Topical Anesthetic Spray Due to the Presence of Benzene
- Insight Pharmaceuticals Issues Voluntary Nationwide Recall of TING® 2% Miconazole Nitrate Athlete’s Foot Spray Antifungal Spray Powder Due to the Presence of Benzene
- Prestige Consumer Healthcare Inc. Reports Second Quarter Fiscal 2024 Results
- Prestige Consumer Healthcare Inc. to Release Fiscal 2024 Second Quarter Earnings Results
More ▼
Key statistics
On Friday, Prestige Consumer Healthcare Inc (PBH:NYQ) closed at 64.31, -14.61% below its 52-week high of 75.31, set on Mar 18, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 63.14 |
---|---|
High | 64.34 |
Low | 62.43 |
Bid | -- |
Offer | 70.21 |
Previous close | 62.80 |
Average volume | 281.77k |
---|---|
Shares outstanding | 49.92m |
Free float | 49.25m |
P/E (TTM) | 15.41 |
Market cap | 3.21bn USD |
EPS (TTM) | 4.17 USD |
Data delayed at least 15 minutes, as of Jun 01 2024 00:00 BST.
More ▼